ArticleFrontiers in oncology2025
Adjuvant radiotherapy treatment of chordoid glioma: a case report with a literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Surgical strategies and long-term survival for third ventricle chordoid gliomas: a systematic review and clinical algorithm.Neurosurgical review · 2026Pooled it
- Third Ventricular Chordoid Glioma With TTF-1 Positivity: A Diagnostic and Therapeutic Challenge.Clinical case reports · 2026Article
- Chordoid glioma of the third ventricle: case report of the first successful surgical treatment in Vietnam.International journal of surgery case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chordoid glioma is a rare World Health Organization (WHO) Grade II brain tumor located near the third ventricle. Fewer than 100 cases have been reported in the literature, and surgery represents the main treatment option. Due to its typical location, complete surgical resection is uncommon, and the role of adjuvant radiotherapy remains controversial. Methods: Based on a case report, we performed a literature review focused on the potential role of adjuvant radiotherapy for chordoid glioma. We summarized data on patient characteristics, surgical approach and extent of resection, radiotherapy technique and dose, and clinical outcomes. Results: A total of 18 patients from 14 studies were identified. Stereotactic treatments were used more frequently than conventional external beam radiotherapy, with doses ranging from 11.5-18 Gy and 45-59.4 Gy, respectively, and a median local control time of 26 months. Five patients developed disease recurrence after a median of 22.4 months. In the present case, the patient received adjuvant conventional radiotherapy (59.4 Gy/33 fractions) and remains alive after 12 months of follow-up with no major side effects. Conclusions: From the available evidence, modern radiotherapy may be considered a therapeutic tool that combines less invasive surgical procedures with improved local control, potentially reducing the risk of severe postoperative complications. Larger studies with longer follow-up periods are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.